Skip to main content
Caplight Logo









DOC2US

DOC2US

Private
Petaling JayaHealthcare & Life Scienceshttps://doc2us.com/

Last Round

Early Funding

May 21, 2021

Momentum

Top 25%

of companies Caplight tracks

Company Overview

DOC2US operates in Healthcare & Life Sciences and is based in Petaling Jaya. It was founded in 2014.

DOC2US is a healthcare technology company that provides a mobile telemedicine platform for online doctor consultations, electronic prescriptions, and medication delivery services.

Sector

Healthcare & Life Sciences

Verticals

Telemedicine, Pharma Supply Chain, EHR & EMR, Patient Engagement

Business Model

B2B2C

Customer Profile

Usage-Based SaaS, Subscription SaaS, Services & Consulting

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

DOC2US Comparables

Compare DOC2US with similar companies based on industry and business-model similarity.

DOC2US comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Teleme Technologies
92%
DoctorOnCall
92%
FEV3R
87%
Book a demo to see all comparables

For institutional investors. Book with your work email.

DOC2US Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingMay 21, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Shekhar BG Ramjutun

Chief Operating Officer

Executive Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 11, 2026

    Monthly visitors increased 38% MoM.

  • Jun 21, 2026

    Monthly visitors grew 95% MoM, reaching 40.6K.

Book a demo to see all signals

For institutional investors. Book with your work email.

DOC2US Filings

Explore SEC and related filing metadata, where available.

DOC2US filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about DOC2US's valuation, stock price, and market status.

Is DOC2US a public or private company?

DOC2US is a private company.

What is the current stock price of DOC2US?

DOC2US is a private company, so its shares have no public market price. Caplight tracks DOC2US's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is DOC2US worth (valuation)?

Valuation information for DOC2US is not publicly available.

Can I buy DOC2US stock?

DOC2US shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was DOC2US's last funding round?

DOC2US's most recent funding round was Early Funding on May 21, 2021.

Who are the main investors in DOC2US?

Investor information for DOC2US is not publicly disclosed.

Will DOC2US IPO soon?

No public IPO plans have been announced for DOC2US.

How can I track DOC2US secondary market activity?

Caplight tracks bids, offers, and trades in DOC2US's shares on secondary markets.

Firmographic Details

HeadquartersPetaling Jaya
Employee Range14
Year Founded2014
Last FundingMay 21, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?